1.河南中医药大学第二临床医学院,河南省郑州市金水东路156号,450046
2.河南省中医院
13803817796@139.com,(0371)60908742
收稿:2021-07-29,
修回:2021-11-23,
纸质出版:2022-04-02
移动端阅览
王冰,刘舜禹,王振涛等.抗纤益心方对扩张型心肌病模型小鼠心肌组织线粒体质量控制的影响[J].中医杂志,2022,63(07):664-670.
WANG Bing,LIU Shunyu,WANG Zhentao,et al.Effect of Kangxian Yixin Formula (抗纤益心方) on Mitochondrial Quality Control in Myocardial Tissue of Dilated Cardiomyopathy Mice[J].Journal of Traditional Chinese Medicine,2022,63(07):664-670.
王冰,刘舜禹,王振涛等.抗纤益心方对扩张型心肌病模型小鼠心肌组织线粒体质量控制的影响[J].中医杂志,2022,63(07):664-670. DOI: 10.13288/j.11-2166/r.2022.07.011.
WANG Bing,LIU Shunyu,WANG Zhentao,et al.Effect of Kangxian Yixin Formula (抗纤益心方) on Mitochondrial Quality Control in Myocardial Tissue of Dilated Cardiomyopathy Mice[J].Journal of Traditional Chinese Medicine,2022,63(07):664-670. DOI: 10.13288/j.11-2166/r.2022.07.011.
目的
2
探讨抗纤益心方治疗扩张型心肌病(DCM)的可能作用机制。
方法
2
30只cTnT
R141W
转基因 DCM小鼠随机分为模型组、抗纤益心颗粒组、辅酶Q10组,每组10只,另设10只C57BL/6J 小鼠为正常组。辅酶Q10组、抗纤益心颗粒组分别给予辅酶Q10片1.5 mg/(kg·d)、抗纤益心方配方颗粒20.4 g/(kg·d)灌胃,正常组、模型组给予生理盐水7.5 ml/(kg·d)灌胃。干预8周后检测各组小鼠心功能[包括左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)、左室射血分数(LVEF)、左室轴缩短率(FS)],观察心肌组织病理学形态及心肌超微结构,检测心肌组织三磷酸腺苷(ATP)和磷酸肌酸(PCr)含量,线粒体质量控制相关蛋白Drp1、Mff、Mfn1、Opa1、Pink1、Parkin、过氧化物酶体增殖物激活受体γ共激活因子1α(PGC-1α)表达水平。
结果
2
与正常组比较,模型组LVEDD、LVESD增大,LVEF、FS降低(
P
<0.05);心肌细胞排列紊乱,纤维化明显,心脏超微结构损伤明显;PCr含量、PCr/ATP值降低(
P
<0.05),Drp1、Mff、Pink1、Parkin及PGC-1α蛋白表达均减少(
P
<0.05)。与模型组比较,抗纤益心颗粒组、辅酶Q10组LVEDD、LVESD降低,LVEF升高(
P
<0.05);抗纤益心颗粒组、辅酶Q10组心肌细胞形态均有所改善,病理纤维化程度减轻,心脏超微结构损伤减轻;抗纤益心颗粒组PCr含量、PCr/ATP值升高,Mff、Pink1、Parkin、PGC-1α蛋白表达增加(
P
<0.05),辅酶Q10组Pink1、PGC-1α蛋白表达增加(
P
<0.05)。与抗纤益心颗粒组比较,辅酶Q10组Parkin蛋白表达下降(
P
<0.05)。
结论
2
抗纤益心方能有效改善DCM小鼠心功能,其机制可能与调控心肌组织线粒体质量控制有关。
Objective
2
To explore the possible mechanism of
Kangxian Yixin Formula
(抗纤益心方, KYF) in the treatment of dilated cardiomyopathy (DCM).
Methods
2
Thirty cTnT
R141W
transgenic mice with DCM were randomly divided into the model group, KYF group and coenzyme Q10 group, with 10 mice in each group. Ten C57BL /6J mice were set as the normal group. Coenzyme Q10 solution at a dose of 1.5 mg/(kg·d), and KYF at a dose of 20.4 g/(kg·d) were given by gavage to the corresponding coenzyme Q10 group and KYF group, respectively. For the normal group and the model group, normal saline at a dose of 10 ml/(kg·d) were given by gavage. After eight weeks intervention, the cardiac function indicators including left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular ejection fraction (LVEF), and left ventricular fractional shortening (FS) were assessed. The myocardial histopathology and ultrastructure were observed. The levels of adenosine triphosphate (ATP) and creatine phosphate (PCr), as well as the expression levels of mitochondrial quality control-related proteins including Drp1, Mff, Mfn1, Opa1, Pink1, Parkin, and peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α) were detected.
Results
2
Compared to the normal group, the model group had significantly increased LVEDD and LVESD, as well as reduced EF and FS (
P
<0.05). Moreover, in the model group, there were disordered cardiomyocytes, significant fibrosis and damaged ultrastructure; the PCr level and the PCr/ATP ratio significantly decreased (
P
<0.05), and the expressions of Drp1, Mff, Pink1, Parkin and PGC-1α were reduced (
P
<0.05). Compared to those in the model group, LVEDD and LVESD in the KYF group and the coenzyme Q10 group significantly decreased, while LVEF significantly increased (
P
<0.05); the morphology of myocardial cells was improved, and the pathological fibrosis and the cardiac ultrastructural damage were reduced. Moreover, in the KYF group, PCr level and PCr/ATP ratio, as well as expression of Mff, Pink1, Parkin, and PGC-1α significantly increased (
P
<0.05); in the coenzyme Q10 group, the expression of Pink1 and PGC-1α significantly increased (
P
<0.05). Compared to the KYF group, the coenzyme Q10 group had significantly lower expression of Parkin (
P
<0.05).
Conclusion
2
KYF can effectively improve the cardiac function of mice with DCM, the mechanism may be related to the regulation of mitochondrial quality control.
PALUDAN SR , PRADEU T , MASTERS SL , et al . Constitutive immune mechanisms: mediators of host defence and immune regulation [J]. Nat Rev Immunol , 2021 , 21 ( 3 ): 137 - 150 .
MAYTIN M , COLUCCI WS . Molecular and cellular mechanisms of myocardial remodeling [J]. J Nucl Cardiol , 2002 , 9 ( 3 ): 319 - 327 .
QIU Z , WEI Y , SONG Q , et al . The role of myocardial mitochondrial quality control in heart failure [J]. Front Pharmacol , 2019 , 10 : 1404 . doi: 10.3389/fphar. 2019. 01404 http://dx.doi.org/10.3389/fphar.2019.01404 .
郭宗耀 , 王振涛 . 基于蛋白质组学探讨抗纤益心方治疗扩张型心肌病的作用机制 [J]. 中华中医药杂志 , 2020 , 35 ( 11 ): 5734 - 5738 .
冯娟 , 董伟 , 全雄志 , 等 . cTnT R141W 转基因小鼠扩张型心肌病模型的建立 [J]. 中国比较医学杂志 , 2007 , 17 ( 10 ): 563 - 567,621 .
LU D , SHAO HT , GE WP , et al . Ginsenoside-Rb1 and tetramethylpyrazine phosphate act synergistically to prevent dilated cardiomyopathy in cTnT R141W transgenic mice [J]. J Cardiovasc Pharmacol , 2012 , 59 ( 5 ): 426 - 433 .
魏伟 , 吴希美 , 李元健 . 药理实验方法学 [M]. 4版 . 北京 : 人民卫生出版社 , 2010 : 1698 .
杨军用 , 彭佳 , 杨莹骊 , 等 . 郭维琴益气活血、泻肺利水法治疗扩张型心肌病验案1则 [J]. 中医杂志 , 2017 , 58 ( 2 ): 177 - 178 .
罗川晋 , 李先隆 , 吴伟 . 邓铁涛调脾护心法治疗扩张型心肌病心力衰竭经验 [J]. 中医杂志 , 2018 , 59 ( 4 ): 285 - 288 .
王振涛 , 闫京京 , 吴鸿 , 等 . 抗纤益心方对去甲肾上腺素诱导H9c2心肌细胞凋亡及凋亡相关因子表达的影响 [J]. 中医杂志 , 2019 , 60 ( 21 ): 1866 - 1869 .
常红波 , 王振涛 , 黑炫鼎 , 等 . 抗纤益心方对扩张型心肌病大鼠心肌能量代谢和解偶联蛋白2的影响 [J]. 中药药理与临床 , 2021 , 37 ( 3 ): 166 - 170 .
MAHMOD M , PAL N , RAYNER J , et al . The interplay between metabolic alterations, diastolic strain rate and exercise capacity in mild heart failure with preserved ejection fraction: a cardiovascular magnetic resonance study [J]. J Cardiovasc Magn Reson , 2018 , 20 ( 1 ): 88 .
PANAGIA M , HE H , BAKA T , et al . Increasing mitochondrial ATP synthesis with butyrate normalizes ADP and contractile function in metabolic heart disease [J]. NMR Biomed , 2020 , 33 ( 5 ): e4258 .
王振涛 , 韩丽华 , 柴松波 , 等 . 抗纤益心方对扩张型心肌病心力衰竭大鼠心肌基质金属蛋白酶-1及其抑制剂表达的影响 [J]. 中医杂志 , 2011 , 52 ( 16 ): 1406 - 1408 .
SONG M , MIHARA K , CHEN Y , et al . Mitochondrial fission and fusion factors reciprocally orchestrate mitophagic culling in mouse hearts and cultured fibroblasts [J]. Cell Metab , 2015 , 21 ( 2 ) : 273 - 286 .
CHAN DC . Fusion and fission: interlinked processes critical for mitochondrial health [J]. Annu Rev Genet , 2012 , 46 : 265 - 287 . doi: 10.1146/annurev-genet-110410-132529 http://dx.doi.org/10.1146/annurev-genet-110410-132529 .
CHEN Y , LIU Y , DORN GN . Mitochondrial fusion is essential for organelle function and cardiac homeostasis [J]. Circ Res , 2011 , 109 ( 12 ): 1327 - 1331 .
MEYER JN , LEUTHNER TC , LUZ AL . Mitochondrial fusion, fission, and mitochondrial toxicity [J]. Toxicology , 2017 , 391 : 42 - 53 . doi: 10.1016/j.tox. 2017. 07. 019 http://dx.doi.org/10.1016/j.tox.2017.07.019 .
WANG P , WANG L , LU J , et al . SESN2 protects against doxorubicin-induced cardiomyopathy via rescuing mitophagy and improving mitochondrial function [J]. J Mol Cell Cardiol , 2019 , 133 : 125 - 137 . doi: 10.1016/j.yjmcc.2019.06.005 http://dx.doi.org/10.1016/j.yjmcc.2019.06.005 .
BAKULA D , SCHEIBYE-KNUDSEN M . Mitoph aging: mitophagy in aging and disease [J]. Front Cell Dev Biol , 2020 , 8 : 239 . doi: 10.3389/fcell.2020.00239 http://dx.doi.org/10.3389/fcell.2020.00239 .
夏冉 , 王茎 , 戴小华 , 等 . 益气活血类中药干预线粒体质量控制治疗心力衰竭的实验研究进展 [J]. 中国实验方剂学杂志 , 2021 , 27 ( 5 ): 206 - 213 .
SIOKA , SABRY AD , CAWLEYl KM , et al . Multiple Levels of PGC-1α Dysregulation in Heart Failure [J]. Front Cardiovasc Med , 2020 , 7 : 2 . doi: 10.3389/fcvm. 2020.00002 http://dx.doi.org/10.3389/fcvm.2020.00002 .
PUNITHAVATHI VR , SHANMUGAPRIYA K , PRINCE PS . Protective effects of rutin on mitochondrial damage in isoproterenol-induced cardiotoxic rats: an in vivo and in vitro study [J]. Cardiovasc Toxicol , 2010 , 10 ( 3 ): 181 - 189 .
FOTINO AD , THOMPSON-PAUL AM , BAZZANO LA . Effect of coenzyme Q10 supplementation on heart failure: a meta-analysis [J]. Am J Clin Nutr , 2013 , 97 ( 2 ): 268 - 275 .
0
浏览量
3
下载量
3
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号